- Home
- RDCM vs XGN Comparison
RDCM vs XGN Comparison
Compare RDCM & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- XGN
- Stock Information
- Founded
- RDCM 1985
- XGN 2002
- Country
- RDCM Israel
- XGN United States
- Employees
- RDCM N/A
- XGN N/A
- Industry
- RDCM Computer peripheral equipment
- XGN Medical Specialities
- Sector
- RDCM Technology
- XGN Health Care
- Exchange
- RDCM Nasdaq
- XGN Nasdaq
- Market Cap
- RDCM 203.7M
- XGN 210.4M
- IPO Year
- RDCM 1997
- XGN 2019
- Fundamental
- Price
- RDCM $13.82
- XGN $11.73
- Analyst Decision
- RDCM Strong Buy
- XGN Strong Buy
- Analyst Count
- RDCM 1
- XGN 5
- Target Price
- RDCM $18.00
- XGN $12.00
- AVG Volume (30 Days)
- RDCM 52.5K
- XGN 286.8K
- Earning Date
- RDCM 11-12-2025
- XGN 11-11-2025
- Dividend Yield
- RDCM N/A
- XGN N/A
- EPS Growth
- RDCM 79.61
- XGN N/A
- EPS
- RDCM 0.56
- XGN N/A
- Revenue
- RDCM $66,334,000.00
- XGN $58,862,000.00
- Revenue This Year
- RDCM $18.07
- XGN $22.28
- Revenue Next Year
- RDCM $11.52
- XGN $14.03
- P/E Ratio
- RDCM $23.90
- XGN N/A
- Revenue Growth
- RDCM 18.18
- XGN 3.89
- 52 Week Low
- RDCM $9.81
- XGN $2.38
- 52 Week High
- RDCM $15.98
- XGN $11.99
- Technical
- Relative Strength Index (RSI)
- RDCM 47.65
- XGN 67.60
- Support Level
- RDCM $13.05
- XGN $11.35
- Resistance Level
- RDCM $14.16
- XGN $11.99
- Average True Range (ATR)
- RDCM 0.55
- XGN 0.34
- MACD
- RDCM -0.09
- XGN 0.04
- Stochastic Oscillator
- RDCM 37.16
- XGN 80.95
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.